Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Oxazepam

FDA-approved product (capsule, oral), marketed as Oxazepam, Serax, Zaxopam.

Registered studies
14
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Oxazepam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Anxiety
  • Anxiety disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

14registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Oxazepam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxazepam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Virtual Reality to Reduce Periprocedural Anxiety During Invasive Coronary Angiography

    NCT06215456 · start 2023-09-18

    Registered record
    Registry ID
    NCT06215456
    Conditions
    Anxiety; Anxiety State
    Interventions
    Virtual reality therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-09-18
    Completion
    2024-04-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety; Anxiety State
    InterventionVirtual reality therapy
    PhaseNot applicable
    Registry statusUnknown

  • Study of EMB-001 as a Potential Smoking Cessation Treatment

    NCT04933916 · start 2021-06-10

    Registered record
    Registry ID
    NCT04933916
    Conditions
    Tobacco Use Disorder
    Interventions
    EMB-001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-06-10
    Completion
    2023-05-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTobacco Use Disorder
    InterventionEMB-001
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

    NCT04868253 · start 2021-05-19

    Registered record
    Registry ID
    NCT04868253
    Conditions
    Smoking Cessation; Tobacco Use Disorder
    Interventions
    EMB-01
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-05-19
    Completion
    2021-12-31
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking Cessation; Tobacco Use Disorder
    InterventionEMB-01
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder

    NCT04501874 · start 2020-07-29

    Registered record
    Registry ID
    NCT04501874
    Conditions
    Cocaine Use Disorder
    Interventions
    EMB-001; EMB-001 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-07-29
    Completion
    2022-10-15
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Use Disorder
    InterventionEMB-001; EMB-001 Placebo
    PhasePhase 2
    Registry statusCompleted

  • Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations

    NCT03404817 · start 2018-03-01

    Registered record
    Registry ID
    NCT03404817
    Conditions
    Cocaine Use Disorder
    Interventions
    Original formulation EMB-001; New formulation EMB-001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-03-01
    Completion
    2018-06-07
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Use Disorder
    InterventionOriginal formulation EMB-001; New formulation EMB-001
    PhasePhase 1
    Registry statusCompleted

  • A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

    NCT02856854 · start 2016-07

    Registered record
    Registry ID
    NCT02856854
    Conditions
    Cocaine Use Disorder
    Interventions
    EMB-001; Placebo; Cocaine IV; Saline IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-07-25
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Use Disorder
    InterventionEMB-001; Placebo; Cocaine IV; Saline IV
    PhasePhase 1
    Registry statusCompleted

  • Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)

    NCT02406066 · start 2015-03

    Registered record
    Registry ID
    NCT02406066
    Conditions
    Cocaine Use Disorder; Tobacco Use Disorder
    Interventions
    metyrapone & oxazepam; metyrapone & oxazepam; metyrapone & oxazepam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-03
    Completion
    2016-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Use Disorder; Tobacco Use Disorder
    Interventionmetyrapone & oxazepam; metyrapone & oxazepam; metyrapone & oxazepam; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers

    NCT02570581 · start 2014-06

    Registered record
    Registry ID
    NCT02570581
    Conditions
    Healthy
    Interventions
    Jelly with:Paracetamol; Jelly with Furosemide; Jelly with Levothyroxine sodium salt; Jelly with Memantine; Jelly with Zopiclone; Jelly with Alprazolam; Jelly with Oxazepam; Jelly with Donepezil; Jelly with Clopidogrel; Jelly with Ramipril; Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam; Plain jelly control; Apple compote Paracetamol; Apple compote Furosemide; Apple compote Levothyroxine sodium salt; Apple compote Memantine; Apple compote Zopiclone; Apple compote Alprazolam; Apple compote Oxazepam; Apple compote Donepezil; Apple compote Clopidogrel; Apple compote Ramipril; Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam; Plain apple compote control
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-06
    Completion
    2014-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJelly with:Paracetamol; Jelly with Furosemide; Jelly with Levothyroxine sodium salt; Jelly with Memantine +20 more
    PhasePhase 1
    Registry statusCompleted

  • Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

    NCT01967381 · start 2013-10

    Registered record
    Registry ID
    NCT01967381
    Conditions
    Methamphetamine Abuse; Methamphetamine Dependence
    Interventions
    Methamphetamine (Desoxyn®)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2018-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethamphetamine Abuse; Methamphetamine Dependence
    InterventionMethamphetamine (Desoxyn®)
    PhaseEarly phase 1
    Registry statusCompleted

  • A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

    NCT00567814 · start 2007-12

    Registered record
    Registry ID
    NCT00567814
    Conditions
    Cocaine Dependence; Cocaine Addiction
    Interventions
    Metyrapone; Oxazepam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-11
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence; Cocaine Addiction
    InterventionMetyrapone; Oxazepam; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets

    NCT02273453 · start 2003-02

    Registered record
    Registry ID
    NCT02273453
    Conditions
    Healthy
    Interventions
    Songha® Night; Oxazepam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-02
    Completion
    Not recorded
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSongha® Night; Oxazepam; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome

    NCT02090504 · start 2002-02

    Registered record
    Registry ID
    NCT02090504
    Conditions
    Alcohol Withdrawal Syndrome; Alcohol Dependence
    Interventions
    Sodium Oxybate (SMO); Oxazepam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-02
    Completion
    2009-05
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Withdrawal Syndrome; Alcohol Dependence
    InterventionSodium Oxybate (SMO); Oxazepam
    PhasePhase 4
    Registry statusCompleted

  • The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient

    NCT00000661

    Registered record
    Registry ID
    NCT00000661
    Conditions
    HIV Infections
    Interventions
    Oxazepam; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionOxazepam; Zidovudine
    PhasePhase 1
    Registry statusCompleted